DATA ELEMENTS NEEDED FOR QUALITY ASSESSMENT COPYRIGHT NOTICE

Washington University grants permission to use and reproduce the *Data Elements Needed for Quality Assessment* exactly as it appears in the PDF available here without modification or editing of any kind solely for end user use in investigating rhinosinusitis in clinical care or research (the "Purpose"). For the avoidance of doubt, the Purpose does not include the (i) sale, distribution or transfer of the *Data Elements Needed for Quality Assessment* or copies thereof for any consideration or commercial value; (ii) the creation of any derivative works, including translations; and/or (iii) use of the *Data Elements Needed for Quality Assessment* as a marketing tool for the sale of any drug. All copies of the *Data Elements Needed for Quality Assessment* shall include the following notice: "All rights reserved. Washington University in St. Louis, Missouri." Please contact Jay F. Piccirillo (314-362-8641) for use of the *Data Elements Needed for Quality Assessment* for any other intended purpose.

"All rights reserved. Washington University in St. Louis, Missouri."
Data Elements Needed for Quality Assessment

Jay F. Piccirillo, MD, FACS
Washington University School of Medicine
St. Louis, Missouri
Introduction

- Patients with cancer often have other diseases, illnesses, or conditions in addition to their index cancer
- These other conditions are generally referred to as *comorbidities*
- Although not a feature of the cancer itself, comorbidity is an important attribute of the patient
- Comorbidity has direct impact on the care of patients and the assessment of the quality of care
Comorbidity Impact on Therapy

- The use of preferred therapy might be contraindicated due to the presence of comorbid ailments

- There are two distinct ways that comorbid ailments might impact on type of therapy
The comorbid ailment(s) may render an overall prognosis so poor for the patient that she may be denied an otherwise desirable treatment for the index cancer.

A particular type of comorbid ailment(s) may affect the patient's ability to tolerate a particular type of therapy.
Prostate Cancer Example

- Desch et al studied treatment recommendations for local or regional prostate cancer.
- As comorbidity increased, the proportion of men receiving no treatment rose correspondingly.
- Fewer than 30% of men with the most significant level of comorbidity received surgery, radiation therapy, or combinations of aggressive therapy as compared with almost 55% of men who had no comorbid ailments.
Greenfield et al conducted a retrospective review to examine whether physicians provide less vigorous treatment for elderly patients with breast cancer.

Sample included women with breast carcinoma that received their primary cancer management at one of seven hospitals in southern California.

Appropriate treatment defined according to criteria map that incorporates widely accepted practice standards.
### Relation of the Comorbidity Index (CI) to Physician Management of Breast Cancer

<table>
<thead>
<tr>
<th>CI Score</th>
<th>Inappropriate</th>
<th>Appropriate</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1</td>
<td>53 (19)</td>
<td>231 (81)</td>
<td>284</td>
</tr>
<tr>
<td>2</td>
<td>37 (41)</td>
<td>53 (59)</td>
<td>90</td>
</tr>
<tr>
<td>Total</td>
<td>90 (24)</td>
<td>284 (76)</td>
<td>374 (100)</td>
</tr>
</tbody>
</table>

P<0.001 $\chi^2=17.640$ Yates corrected
Head and Neck Cancer Example

<table>
<thead>
<tr>
<th>Prognostic Comorbidity</th>
<th>Initial Treatment</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Radiation Therapy Only</td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>84/311 (27%)</td>
<td>1.0</td>
</tr>
<tr>
<td>Present</td>
<td>23/45 (51%)</td>
<td>2.82 (1.50-5.29)</td>
</tr>
<tr>
<td>Total</td>
<td>107/356 (30%)</td>
<td></td>
</tr>
</tbody>
</table>
Quality of Care Example

Greenfield et al studied whether differences in mortality rates for 969 patients with incident cases of breast, colorectal, and prostate cancers across seven hospitals in southern California could be accounted for, in part, by patient's differing levels of comorbidity on admission
Of the seven hospitals, the three with the highest mortality had been pinpointed by the *Los Angeles Times* as high mortality outliers.

The percentage of patients with severe comorbidity scores ranged from 9% to 18% across the seven hospitals (p<0.01).

The rankings of hospitals varied depending on whether one adjusted for age, comorbidity level, or cancer stage.
Begg et al used the SEER-Medicare linked database to study the relationship between the volume of major cancer surgeries performed and the hospital operative mortality rate.

The investigators used the Medicare discharge summary from the index hospitalization to generate a comorbidity severity score.
Higher surgical volume was linked with lower mortality

This volume -- mortality relationship persisted even after adjustment for age and comorbidity

By having comorbidity information, the authors were able to rebut the complaint that high volume hospitals were, in some way, selecting less sick patients
Comorbidity assessment important even when it is not independently statistically significant

Hillner found decrease likelihood of axillary node dissection with increasing comorbidity

After adjusting for age and size of primary tumor, comorbidity no longer associated with node dissection

Inclusion of comorbidity allowed for more robust conclusions about age
Poor Quality of Care?
Sound Clinical Judgment?
Comorbidity Instruments

- Several instruments have been developed to classify different comorbid diseases and to quantify the severity of the overall comorbid condition.
- None of the instruments were specifically designed to study comorbidity in cancer patients.
- Nevertheless, these instruments have been used to classify comorbidity in several types of cancers and have performed well.
Instruments to measure the severity of comorbidity can be classified into four mutually exclusive groups depending on the

• origin of the data
  (medical record review vs. claims-based)

• applicability of the instrument
  (general vs. disease-specific)
Medical Record Review

- Kaplan-Feinstein Index
- Charlson Comorbidity Index
- The Index of Co-Existent Disease
Kaplan-Feinstein Index

- Developed from the study of comorbidity in patients with diabetes mellitus
- The KFI has been used to study the impact of comorbidity in several cancers
- Specific diseases and conditions are classified into four groups-- none, mild, moderate, or severe according to severity of organ decompensation and prognostic impact

Example

Peripheral Arterial Disease

- Mild – Untreated thoracic or abdominal aneurysm (< 6 cm)
- Moderate – Bypass or amputation for gangrene or arterial insufficiency > 6 months ago
- Severe – Untreated thoracic or abdominal aneurysm (> 6 cm)
Overall Comorbidity Score

- Highest ranked single ailment

- In cases where two or more Moderate ailments occur in different organ systems, the Overall Comorbidity Score should be designated as Severe
<table>
<thead>
<tr>
<th>CONDITION</th>
<th>DECOMPENSATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial Infarct more than 6 months ago</td>
<td>Moderate</td>
</tr>
<tr>
<td>DBP 90-114 mm Hg</td>
<td>Mild</td>
</tr>
<tr>
<td>History of alcohol abuse, but not presently drinking</td>
<td>Mild</td>
</tr>
<tr>
<td>Overall Comorbidity Score</td>
<td>Moderate</td>
</tr>
</tbody>
</table>
### Example

<table>
<thead>
<tr>
<th>CONDITION</th>
<th>DECOMPENSATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic exertional angina</td>
<td>Moderate</td>
</tr>
<tr>
<td>Major depression controlled with medication</td>
<td>Mild</td>
</tr>
<tr>
<td>Diabetes requiring insulin</td>
<td>Moderate</td>
</tr>
<tr>
<td>Overall Comorbidity Score</td>
<td>Severe</td>
</tr>
</tbody>
</table>
**Charlson Comorbidity Index (CCI)**

- Developed from studies of one-year mortality for patients admitted to a medical unit of a teaching hospital
- Scores for comorbid diseases derived from a weighted index based on the adjusted relative risk of mortality associated with each disease
- Total score is sum of weighted scores

Index of Co-Existent Disease (ICED)

- Designed to predict LOS and resource utilization after hospitalization
- Instrument assesses patient status in two domains
  - Individual Disease Severity (IDS)
    - reflects severity of health categories (0-4)
  - Functional Severity
    - assesses physical impairment before treatment (0-2)
- Peak intensities for each domain are grouped to give ICED score (0-3)

Inclusion of Comorbidity into Oncology Data Registries

- Educational program developed to train CTRs to code comorbidity from the medical record
- Program consisted of an introduction to the importance of comorbidity, the use of comorbidity instrument and documentation book, and many clinical examples
- The entire educational session lasted 10 hours
- CTRs demonstrated excellent performance
Claims-Based

- Modifications of Charlson
  - Dartmouth-Manitoba ICD-9 conversion algorithm
  - Deyo et al
  - Ghali et al

- Von Korff et al chronic disease score from automated pharmacy records
## Charlson Comorbidity Index—Electronic Version

<table>
<thead>
<tr>
<th>Assigned weights for diseases</th>
<th>Conditions</th>
<th>ICD-9-CM Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Hemiplegia</td>
<td>344.1, 342-342.9</td>
</tr>
<tr>
<td></td>
<td>Moderate or sever renal disease</td>
<td>582-582.9, 583-583.7, 585, 586, 588-588.9</td>
</tr>
<tr>
<td></td>
<td>Diabetes with end organ damage</td>
<td>250.4-250.6</td>
</tr>
<tr>
<td></td>
<td>Any tumor</td>
<td>140-172.9, 174-195.8</td>
</tr>
<tr>
<td></td>
<td>Leukemia</td>
<td>204-208.9</td>
</tr>
<tr>
<td></td>
<td>Lymphoma</td>
<td>200-203.8</td>
</tr>
<tr>
<td>3</td>
<td>Moderate or severe liver disease</td>
<td>572.2-572.8, 456.0-456.21</td>
</tr>
<tr>
<td>6</td>
<td>Metastatic solid tumor</td>
<td>196-199.1</td>
</tr>
<tr>
<td></td>
<td>AIDS</td>
<td>042-044.9</td>
</tr>
</tbody>
</table>
Impact of Methods of Assessment

- Concato et al studied the association of comorbidity, as assessed by medical record review, and operative mortality after transurethral resection of the prostate (TURP) and open prostectomy (OPEN) for patients with benign prostatic hypertrophy.

- Previous research, using administrative databases, had shown the relative risk of 5-year mortality for TURP was elevated, relative to OPEN.
These findings were counter-intuitive since TURP is a less invasive procedure and would be expected to have lower mortality rates.

In addition, procedure-associated mortality would be expected to occur within 30 days of the procedure and would not be significant at five-year follow-up.
Concato performed detailed chart review to assign levels of comorbidity based on several different comorbidity indices to 250 men undergoing TURP or OPEN prostectomy between 1979 and 1981.

For the TURP group, the crude 5-year mortality rate was 17.5% (22 of 126 patients) and for the OPEN group 13.5% (17 of 126 patients).

Patients who received TURP were older and had a higher level of comorbidity than patients undergoing OPEN.
As the detail and quality of the assessment of comorbidity increased, the adjusted risk of mortality after TURP decreased.

Concato concluded that comorbidity adjustment is complex and that inadequate or incomplete assessment of comorbidity may lead to false conclusions regarding relative treatment effectiveness.
Medical Record Approach

- Comorbidity severity can be assigned to a majority of patients within tumor registry

- Very accurate assessment of comorbidity

- Comorbidity coding added approximately 3% additional work effort
Claims-Based Approach

- Available in many states for many people
- Attractive alternative to more expensive methods of ascertaining comorbidity
- Claims-based databases may not be available for all patients in a tumor registry
- Less accurate assessment
Conclusions

- Comorbidity impacts on screening, diagnosis, treatment, and prognosis
- Valid comorbidity instruments exist
- Comorbidity can be derived from medical records or claims-based
- Medical record approach more accurate and complete
- Claims-based approach less expensive
Recommendations

- Comorbidity should be required data element for all studies of the patterns and quality of cancer care
- Claims-based approach first step for inclusion of comorbidity
- Medical-records approach second step with cancer registry staff training and incorporation into hospital-based, state, and national cancer registries
- Special studies, such as SEER, NCDB, should employ medical record review whenever possible